E3 PreliminaryPreliminaryPEM not requiredPeer-reviewedReviewed
Standard · 3 min
Could Modafinil Be an Option in the Treatment of Sexual Dysfunctions Due to Antidepressant Use in Women? Two Case Reports.
Yilbaş, Barış · Turk psikiyatri dergisi = Turkish journal of psychiatry · 2022 · DOI
Quick Summary
Some antidepressant medications can cause sexual side effects like loss of desire and difficulty with arousal. This report describes two women whose sexual problems improved when modafinil (a medication used for sleep disorders and fatigue) was added to their antidepressant treatment. One woman saw significant improvement at 100 mg daily, while the other needed 200 mg daily to see meaningful improvement.
Why It Matters
For ME/CFS patients, this study is relevant because many require antidepressants for comorbid depression and fatigue management, and sexual dysfunction is an underrecognized but significant quality-of-life issue. Modafinil is already used in some ME/CFS patients for fatigue, making potential dual benefits worth exploring. Understanding medication side effects and potential remedies helps patients make informed treatment decisions.
Observed Findings
Patient 1 (age 39): Marked decrease in sexual desire loss, decreased arousal, and orgasm difficulties one month after modafinil 100 mg/day initiation.
Patient 2 (age 43): Slight improvement with modafinil 100 mg/day; significant improvement after dose increase to 200 mg/day.
Both patients had sexual dysfunction onset after antidepressant initiation with no prior sexual history problems.
Both patients wanted to continue current antidepressant treatment and sought alternative solutions.
Inferred Conclusions
Modafinil may counteract antidepressant-induced sexual dysfunction through dopaminergic and noradrenergic mechanisms.
Modafinil dose may need individualization, with some patients requiring 200 mg/day for clinically meaningful benefit.
Adjunctive modafinil could be a treatment option for patients who experience sexual dysfunction with antidepressants but wish to maintain their current psychiatric medication regimen.
Remaining Questions
Does modafinil effectiveness for antidepressant-induced sexual dysfunction generalize to larger, diverse patient populations across different antidepressant classes?
What is the optimal dose range and duration of modafinil treatment for this indication?
What This Study Does Not Prove
This case report does not prove modafinil is effective for antidepressant-induced sexual dysfunction in a broader population—two cases cannot establish efficacy or safety across different patients, ages, antidepressant types, or underlying conditions. It does not establish causation or rule out placebo effect, spontaneous improvement, or other confounding factors. Generalizability to ME/CFS populations specifically is unclear.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.